New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology

Bouchra Derraz,Gabriele Breda,Christoph Kaempf,Franziska Baenke,Fabienne Cotte,Kristin Reiche,Ulrike Köhl,Jakob Nikolas Kather,Deborah Eskenazy,Stephen Gilbert

DOI: https://doi.org/10.1038/s41698-024-00517-w

2024-01-30

npj Precision Oncology

Abstract:Abstract Until recently the application of artificial intelligence (AI) in precision oncology was confined to activities in drug development and had limited impact on the personalisation of therapy. Now, a number of approaches have been proposed for the personalisation of drug and cell therapies with AI applied to therapy design, planning and delivery at the patient’s bedside. Some drug and cell-based therapies are already tuneable to the individual to optimise efficacy, to reduce toxicity, to adapt the dosing regime, to design combination therapy approaches and, preclinically, even to personalise the receptor design of cell therapies. Developments in AI-based healthcare are accelerating through the adoption of foundation models, and generalist medical AI models have been proposed. The application of these approaches in therapy design is already being explored and realistic short-term advances include the application to the personalised design and delivery of drugs and cell therapies. With this pace of development, the limiting step to adoption will likely be the capacity and appropriateness of regulatory frameworks. This article explores emerging concepts and new ideas for the regulation of AI-enabled personalised cancer therapies in the context of existing and in development governance frameworks.

oncology

What problem does this paper attempt to address?

The paper primarily explores the regulatory challenges faced by AI-based personalized drugs and cell therapies in precision oncology and proposes corresponding solutions. Specifically, the paper attempts to address the following key issues:

1. **Regulatory Lag**: The current regulatory framework cannot keep up with the rapid development of personalized treatment technologies, leading patients to believe that regulatory bodies unnecessarily delay the application of life-saving therapies.

2. **Regulatory Framework for Personalized Therapies**: The existing regulatory system is not yet adequately prepared for AI-based personalized cancer treatments (including classical drugs and Advanced Therapy Medicinal Products, ATMPs). Especially for ATMPs, the approval time in the US and the EU is very long, which limits the clinical application of these therapies.

3. **Interaction Between Different Technologies**: As the integration of digital technologies and AI in the medical field increases, existing regulations have not fully considered the interaction of these technologies in actual medical processes.

4. **Regulatory Challenges of New Personalized Therapies**: For example, highly personalized treatment methods such as using AI for cell therapy receptor design, the current regulatory framework struggles to address the challenges brought by these new technologies.

Through a detailed comparative analysis of the regulatory systems in the US and the EU, the paper points out the existing regulatory issues and proposes a series of innovative suggestions to optimize the approval process to better support the development of AI-driven personalized cancer treatments.